Collaborator:
Christian Doppler Laboratory Applied Metabolomics
Studienleiter
Alexander Haug, MD Principal Investigator Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna
Medical University of Vienna 1090 Vienna AustriaRekrutierend» Google-Maps Ansprechpartner: Johannes Laengle, MD, PhD Phone: +43 1 40400 69260 E-Mail: johannes.laengle@meduniwien.ac.at
1. Intratumoral changes of PD-L1 expression during neoadjuvant CRT/SCPRT (Time Frame - 3 weeks): Intratumoral PD-L1 expression dynamics induced by neoadjuvant CRT/SCPRT will be assessed by 89Zr-atezolizumab PET imaging (day 0 and between day 10-14).
Secondary outcome:
1. Radiographic therapy response (Time Frame - 12 weeks): Radiographic therapy response will be determined by magnetic resonance imaging-assessed tumor regression grade (mrTRG) for rectal cancer and PET response criteria in solid tumors (PERCIST) for esophageal cancer.
2. Pathological therapy response (Time Frame - 12 weeks): Pathological therapy response will be determined according to the latest American Joint Committee on Cancer/International Union Against Cancer-Tumor Node Metastasis (AJCC/UICC-TNM) staging and tumor regression grade (TRG).
CRT: 50 Gy in 2 Gy fractions over 25 working days + capecitabine 1650 mg/m2/d PO
SCPRT: 25 Gy in 5 Gy fractions over 5 working days
CROSS Protocol: 41.4 Gy in 1.8 Gy fractions over 23 working days + carboplatin AUC of 2 mg/ml/min + paclitaxel 50 mg/m2 IV Q1W
PD-L1 PET: 10 mg atezolizumab IV followed by 37 MBq 89Zr-atezolizumab IV. PET imaging will be done before neoadjuvant CRT/SCPRT (day 0) and between day 10-14 during CRT/SCPRT.
Quelle: ClinicalTrials.gov
Sie können folgenden Inhalt einem Kollegen empfehlen:
"PD-L1 PET Imaging During Neoadjuvant (Chemo)Radiotherapy in Esophageal and Rectal Cancer"
Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.
Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!